Long-term thionamide antithyroid treatment of Graves' disease.
Graves' hyperthyroidism
antithyroid drugs
long-term treatment
methimazole
thionamide
Journal
Best practice & research. Clinical endocrinology & metabolism
ISSN: 1878-1594
Titre abrégé: Best Pract Res Clin Endocrinol Metab
Pays: Netherlands
ID NLM: 101120682
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
pubmed:
21
4
2022
medline:
22
3
2023
entrez:
20
4
2022
Statut:
ppublish
Résumé
Thionamide antithyroid drugs (ATD) are the treatment of choice for Graves' hyperthyroidism. The major drawback of ATD treatment for 1-2 years is the relapse of hyperthyroidism in about 50% of patients. Recently, it has been shown that ATD treatment for more than five years is accompanied by long-term remission in majority of patients without additional major side effects in both adults and children. Compared to radioactive iodine therapy, long-term ATD results in more favorable outcomes. This review summarizes the evidence on long-term ATD therapy regarding the remission rate of hyperthyroidism, efficacy and safety, indications and mode of therapy in patients with hyperthyroidism.
Identifiants
pubmed: 35440398
pii: S1521-690X(22)00018-5
doi: 10.1016/j.beem.2022.101631
pii:
doi:
Substances chimiques
Methimazole
554Z48XN5E
Iodine Radioisotopes
0
Antithyroid Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101631Informations de copyright
Copyright © 2022. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of competing interest There is no funding. None of the authors have any conflict of interest.